Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston's Promus Element CE marked for larger group of patients

This article was originally published in Clinica

Executive Summary

Boston Scientific has CE marked its Promus Element everolimus-eluting stent for use in patients with diabetes mellitus and those experiencing an acute myocardial infarction (AMI). The Natick, Massachusetts firm says that the new indications are "important additions, especially as the prevalence of diabetes continues to increase dramatically worldwide". Promus Element was originally CE marked for sale in Europe in late 2009 (www.clinica.co.uk, 3 November 2009). Approval in both the US and Japan is expected in mid-2012.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT095652

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel